Working with the pharmaceutical and medical technologies industry

At Alzheimer’s Society, we’re working towards a world where dementia no longer devastates lives. We do this through providing vital information and support, campaigning for rights, and funding pioneering research. 

We welcome partnerships and funding from other sectors that accelerate progress in ending the devastation of dementia. 

We recognise the role of the pharmaceutical medical technologies (med-tech) industry that surrounds dementia research, policy, innovation, and the development of new treatments. 

As a charity which plays a key part of those systems, we believe it’s important to work in partnership when there are areas of interest and goals we share with these industries. 

Collaborating in the areas where we feel we can make most difference has the potential not only to support this progress, but bring about new opportunities, data, and insight. By working together, we can deliver significant impact for people affected by dementia.

We commit to following a clear policy to ensure we maintain our integrity and independence, as well as transparency in our relationships. All partnerships must bring progress and benefit to people affected by dementia, today and in the future. 

Our key commitments for working with the med-tech industry

This statement sets out our key commitments in working with the pharmaceutical and medical technologies industry:

1. Uphold our principles of independence and impartiality 

   We acknowledge the importance of maintaining independence and will never compromise our ethics and integrity as part of a partnership with the pharmaceutical industry.

2. Open and transparent

   Partnering with the industry can facilitate platforms and opportunities to share knowledge and expertise within the dementia space. We commit to being open and transparent about our relationships with the industry, which in turn, ensures we maintain our independence and integrity.

3. Responsible partnerships and financial support 

   Financial support can provide a vital contribution towards delivering impact and progress for dementia. 

   We will ensure all partnerships comply with the relevant laws and regulations, as well as best practice. This includes understanding industry’s obligations under the Association of the British Pharmaceutical Industry’s Code of Practice (ABPI). 

   We will also conduct due diligence on each prospective partnership, which if successful, will be governed by formalised agreements which outline requirements and expectations from each party. 

   The total amount of income received from the industry in one year will not exceed 5% of our total income, ensuring we adhere to best practice in the sector. We will declare all financial income at the end of each financial year.